Revelation Biosciences adopts bylaw amendments, authorizes reverse stock split

REVELATION BIOSCIENCES, INC.

Board approved amended employment agreements for CEO & CFO: 2x salary+bonus severance on change in control, 18-mo COBRA, 3-year term.
Stockholders authorized reverse stock split up to 1:250 within one year, allowing Board to fix ratio without further approval.
Bylaws updated: universal proxy rule compliance, formal 'Cause' definition for officers/directors, removal only for cause due to classified board.
Elected Jennifer Carver as Class A director to serve until 2029 annual meeting; ratified Baker Tilly as auditor for FY2026.
Emergency succession framework added for CEO/CFO vacancies: CFO assumes CEO duties, CEO assumes CFO duties pending Board action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.